Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-06-19
2007-06-19
Saucier, Sandra E. (Department: 1651)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S303000, C514S001000, C514S585000
Reexamination Certificate
active
10475505
ABSTRACT:
Disclosed herein are compositions and methods used to modulate a NH2-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH2-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin sensitivity.
REFERENCES:
patent: 5498631 (1996-03-01), Gorbach et al.
patent: 5506211 (1996-04-01), Barnes et al.
patent: 5837244 (1998-11-01), Karin et al.
patent: 5877309 (1999-03-01), McKay et al.
patent: 6043083 (2000-03-01), Davis et al.
Schroder AK et al. 2004. Insulin resistance in patients with polycystic ovary syndrome. Ann Med. 36:426-39.
Yee B et al. 2004. Neuroendocrine changes in sleep apnea. Curr Opin Pulm Med. 10:475-81.
Choudhury J et al. 2004. Clinical aspects of fatty liver disease. Semin Liver Dis 24: 349-62.
Musso C et al. 2004. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine 83: 209-22.
Ness-Abramof R et al. 2004. Medical therapy for obesity: present and future. Isr Med Assoc J 6: 760-5.
Segal R. 2004. Type 2 diabetes and disease management: exploring the connections. Dis Manag 7 Suppl 1: S11-22.
Muhammad S. 2004. Epidemiology of diabetes and obesity in the United States. Compend Contin Educ Dent 25: 195-8, 200, 202, 204.
Bogoyevitch MA et al. 2004. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta 1697: 89-101.
Plourde G. 2006. Preventing and managing pediatric obesity. Canadian Family Physician 52: 322-328.
Bennett BL. 2003. JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol 3: 420-425.
Jaeschke, Anja et al., “An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue,” Genes & Development 18:1976-1980 (2004).
Jaeschke Anja et al., “Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes,” PNAS 2005 102:6931-6935 (2005).
Kaneto, Hideaki et al., “Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide,” Nature Medicine 10:1128-1132 (2004).
Nakatani, Yoshihisa et al., “Modulation of the JNK Pathway in Liver Affects Insulin Resistance Status,” J. of Biological Chemistry 279:45803-45809 (2004).
Hirosumi, Jiro et al. “A central role for JNK in obesity and insulin resistance,” Nature 420:353-356 (2002).
Chang Lufen
Hotamisligil Gokhan S.
Karin Michael
Barnhart Lora E
Edwards Angell Palmer & & Dodge LLP
Harvard University, President and Fellows of Harvard College
Lauro, Esq. Peter C.
Saucier Sandra E.
LandOfFree
Compositions and methods for modulating NH2-terminal Jun... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for modulating NH2-terminal Jun..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for modulating NH2-terminal Jun... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807807